Clinical Trials Logo

Recurrent Osteosarcoma clinical trials

View clinical trials related to Recurrent Osteosarcoma.

Filter by:

NCT ID: NCT02470091 Completed - Clinical trials for Recurrent Osteosarcoma

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Start date: November 21, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as denosumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02357810 Completed - Clinical trials for Recurrent Osteosarcoma

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Start date: March 21, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02304458 Completed - Metastatic Melanoma Clinical Trials

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Start date: March 30, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether nivolumab works better alone or with ipilimumab in treating patients with recurrent or refractory solid tumors or sarcomas.

NCT ID: NCT02243605 Active, not recruiting - Clinical trials for Recurrent Osteosarcoma

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Start date: December 19, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cabozantinib s-malate works in treating patients with osteosarcoma or Ewing sarcoma that has grown or returned (come back) after a period of improvement. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may also prevent the growth of new blood vessels that tumors need to grow.

NCT ID: NCT02097238 Completed - Clinical trials for Recurrent Osteosarcoma

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Start date: August 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well eribulin mesylate works in treating patients with osteosarcoma that has come back after treatment (recurrent) or has not responded to treatment (refractory). Microtubule inhibitors, such as eribulin mesylate, may stop or slow the growth of tumor cells by disrupting the cell cycle.

NCT ID: NCT02011126 Withdrawn - Rhabdomyosarcoma Clinical Trials

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Start date: June 30, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well imetelstat sodium works in treating younger patients with relapsed or refractory solid tumors. Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01807052 Completed - Clinical trials for Recurrent Osteosarcoma

Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas

Start date: November 2009
Phase: N/A
Study type: Observational

This trial studies biomarker expression in tissue samples from patients with bone sarcomas. Studying biomarker in tissue samples from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer

NCT ID: NCT01614795 Completed - Rhabdomyosarcoma Clinical Trials

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Start date: June 18, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab and temsirolimus together may kill more tumor cells.

NCT ID: NCT01553539 Completed - Clinical trials for Recurrent Osteosarcoma

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Start date: October 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well therapeutic angiotensin-(1-7) works as second-line therapy or third-line therapy in treating patients with metastatic sarcoma that cannot be removed by surgery. Therapeutic angiotensin-(1-7) may stop the growth of sarcoma by blocking blood flow to the tumor. Funding Source - FDA Office of Orphan Drug Products (OOPD)

NCT ID: NCT01374672 Completed - Clinical trials for Recurrent Osteosarcoma

Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma

Start date: July 2011
Phase: N/A
Study type: Observational

This research study is studying biomarkers in predicting response to chemotherapy in samples from young patients with osteosarcoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.